Extract
Mylan v. Warner Chilcott: a study in pharmaceutical product hopping.
No longer available (Autolink)
See the full content of this document
This document cites
- Federal Cases - 335 F.Supp.2d 522 (D.N.J. 2004), 02-2007, In re Remeron Antitrust Litigation
- Federal Cases - 432 F.Supp.2d 408 (D.Del. 2006), Civ. A. 02-1512, Abbott Laboratories v. Teva Pharmaceuticals USA, Inc.
- Federal Cases - 253 F.3d 34 (D.C. Cir. 2001), 00-5212, United States v. Microsoft Corp.
- Federal Cases - 482 F.3d 1330 (Fed. Cir. 2007), 06-1181, Teva Pharmaceuticals USA, Inc. v. Novartis Pharmaceuticals Corp.
- Federal Cases - 534 F.Supp.2d 146 (D.D.C. 2008), C. A. 06-2084, Walgreen Co. v. AstraZeneca Pharmaceuticals L.P.